• Sodium Citrate for SERS Workflows

  2026-09-19

  Sodium citrate provides a practical chemistry-control variable for SERS nanofabrication, from pH management and trace-metal control to sample handling. This guide separates evidence from the 3D Au nanocluster study from recommended citrate-screening workflows, helping researchers improve reproducibility without overstating what the paper demonstrated.

• Verapamil in Hypoxia-Inflammation Assays

  2026-09-18

  Verapamil ((±)-Verapamil) is more than a calcium channel blocker in urothelial hypoxia research. This article explains how exposure duration, ROS-linked signaling, assay endpoints, and pharmacological confounding shape interpretation of verapamil-sensitive inflammasome experiments.

• Viral RIPK3 Degradation and Proteasome-Driven Inflammation

  2026-09-18

  Liu and colleagues identified a viral inducer of RIPK3 degradation, or vIRD, that hijacks the host SCF ubiquitin-ligase machinery to promote proteasome-dependent loss of RIPK3 and suppress necroptosis. Genetic, biochemical, virological, and mouse studies showed that this mechanism links viral evolution with inflammation, replication, and disease severity.

• Fractional Viability in Cancer Drug Response

  2026-09-17

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, separating overall growth inhibition from the degree of cell killing. Its central finding—that drugs can alter proliferation and death in different proportions and on different timelines—supports more interpretable in vitro cancer research and assay design.

• EZ Cap EGFP mRNA 5-moUTP Workflow Guide

  2026-09-17

  Learn how to use EZ Cap EGFP mRNA 5-moUTP as a bright, reproducible reporter for cell-based expression screens, delivery optimization, and fluorescent imaging. The workflow connects Cap1 and 5-moUTP design with practical controls, nanoparticle formulation choices, and troubleshooting decisions.

• PR-619 for DUB Inhibition in Cell Assays

  2026-09-16

  PR-619 is a reversible, cell-permeable deubiquitylating enzymes inhibitor for mapping ubiquitin-dependent proteostasis, autophagy, cancer phenotypes, and neurodegenerative mechanisms. This workflow distinguishes upstream DUB inhibition from direct proteasome blockade and shows how to connect ubiquitin readouts with the oncogenic signaling findings reported in HPV-positive HeLa cells.

• SB203580: Selective p38 MAPK Inhibitor

  2026-09-16

  SB203580 is an ATP-competitive p38 MAPK inhibitor used to interrogate stress, inflammatory, and pain-related signaling. Its reported p38 MAPK IC50 is 0.3–0.5 μM in supplier-reported assays, while the 2024 orofacial pain study supports ROS–p38 signaling as a testable pathway context.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus

  2026-09-15

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based detection. It is intended for research applications such as in situ hybridization and Northern blot hybridization, and should not be used for diagnostic, clinical, therapeutic, or medical workflows.

• 3D Osteocyte Networks Under Pulsatile Flow

  2026-09-15

  Merife and colleagues developed a transparent three-chamber microfluidic platform for studying three-dimensional MLO-Y4 osteocyte networks exposed to pulsatile unidirectional fluid flow stimuli. The model links defined mechanical stimulation with real-time calcium signaling, long-term osteocyte phenotype, and Cx43-dependent network communication.

• 5X Protein Loading Buffer (Reducing): Protocol Guide

  2026-09-14

  5X Protein Loading Buffer (Reducing), SKU K1164, supports denaturing and reducing protein sample preparation before SDS-PAGE electrophoresis by combining SDS, a sulfhydryl reducing agent, buffer salts, and bromophenol blue. It is intended for molecular-weight-based separation under reducing conditions and should not be used when native protein structure, protein complexes, or non-reducing disulfide states must be preserved.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-09-14

  Zhao and colleagues present a standardized whole-blood stimulation protocol for measuring how metabolic interventions reshape human immune responses. The approach combines physiologically relevant blood-based stimulation, defined immune and microbial triggers, metabolic pathway modulation, and cytokine quantification to support reproducible cohort studies and mechanistic immunometabolism research.

• Birinapant (TL32711) for Apoptosis Workflows

  2026-09-13

  Birinapant (TL32711) converts IAP biology into a practical tool for testing caspase-8 activation, TNF-mediated NF-κB inhibition, and TRAIL potency enhancement. This workflow-focused guide connects its SMAC-mimetic mechanism with MDM1–p53 evidence in colorectal cancer, while clearly separating validated findings from recommended pilot conditions.

• Etomoxir: A Decision Framework for Immunometabolism

  2026-09-12

  Etomoxir and R-(+)-Etomoxir are powerful tools for probing fatty acid oxidation and immune metabolism. This article presents an assay-centered framework that separates CPT-1 biology from concentration-dependent confounding and connects whole-blood experiments with carefully bounded neuroinflammation research.

• Viral RIPK3 Degradation and Proteasome-Controlled Inflammati

  2026-09-11

  Liu et al. identified a family of orthopoxvirus proteins, termed viral inducers of RIPK3 degradation, that recruit host SCF machinery to ubiquitinate and eliminate RIPK3, suppressing necroptosis. The study links this proteasome-dependent immune-evasion mechanism to viral replication, inflammation, mortality, and pathogen–host evolution, while providing a framework for dissecting degradation-dependent control of inflammatory cell death.

• Relative and Fractional Viability in Cancer Drug Testing

  2026-09-11

  Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that these measures capture different combinations of proliferative inhibition and cell death. The framework supports better assay design and more cautious interpretation of drug-response data in cancer research.

8554 records 1/571 page Next 12345 下5页 Last page